Hikal Ltd (HIKAL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Hikal Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of Group Conference call for the quarter and half year ended September 30, 2026.
Audio / Video · 04 Nov 2026, 12:56 am
Hikal Releases Audio Recording for Q2 & H1 FY27 Earnings Call Hikal Limited has made available the audio recording of its earnings group conference call for the quarter and half-year ended 30th Sep'26. The call was conducted on 3rd Nov'26 at 5:00 PM IST, pursuant to Regulation 30 of the SEBI LODR Regulations, 2015. Investors and market participants can access the full recording via the official link hosted on the company's website.
Result presentation for the quarter and half year ended September 30, 2026
Investor Presentation · 03 Nov 2026, 9:39 pm
Hikal Reports Q2 FY27 Revenue Growth of 36% YoY With Stronger Operating Margins Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY, driven by a 47% YoY growth in Pharmaceuticals to ₹278 crore and a 21% YoY rise in Crop Protection to ₹156 crore. EBITDA surged 524% YoY to ₹45 crore, expanding margins by 808 bps YoY to 10.3%. Net loss narrowed to ₹6 crore from ₹35 crore in Q2 FY26. For H1 FY27, revenue rose 20% YoY to ₹837 crore, while EBITDA reached ₹82 crore. Management reiterated full-year guidance of mid-teens revenue growth and substantial profitability improvement.
Announcement under Regulation 30 of SEBI LODR 2015- Press Release on the results of the Company for the quarter and half year ended September 30, 2026.
Press Release · 03 Nov 2026, 9:27 pm
Hikal Reports Q2 FY27 Earnings with Strong Revenue and Operational Recovery Hikal reported consolidated revenue of ₹434 crore for Q2 FY27, up 36% YoY and 8% QoQ, driven by recovery in its API portfolio and sustained CDMO execution. Pharmaceuticals revenue rose 47% YoY to ₹278 crore, while Crop Protection grew 21% YoY to ₹156 crore. EBITDA jumped to ₹45 crore with a 10.3% margin, narrowing net loss to ₹6 crore from ₹35 crore YoY. The company signed a multi-year European agrochemical CDMO contract, secured Swissmedic approval, and reiterated mid-teens revenue growth guidance for FY27.
Pursuant to Regulation 30(5) of the SEBI LODR Regulations- List of KMP authorized to determine materiality and make disclosures.
Others (Uncategorized) · 03 Nov 2026, 8:21 pm
Hikal Authorizes Key Managerial Personnel for Materiality Determinations and Disclosures Hikal Limited informed stock exchanges on 3rd Nov'26 that its Board of Directors authorized specific Key Managerial Personnel pursuant to Regulation 30(5) of SEBI LODR Regulations. Chairman & Managing Director Sameer Hiremath has been authorized to determine the materiality of events/information and make disclosures. Additionally, Company Secretary & Compliance Officer Rajasekhar Reddy and Chief Financial Officer Kuldeep Jain are authorized to execute disclosures of material events to the stock exchanges.
Unaudited Financial Results for the quarter and half year ended September 30, 2026
Outcome · 03 Nov 2026, 8:00 pm
Hikal Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 7:57 pm
Unaudited Financial Results for the quarter and half year ended September 30, 2026
Financial Result · 03 Nov 2026, 7:54 pm
Hikal Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 4,342 (+36.3% YoY | +7.8% QoQ) ■ EBITDA: 449 (+523.6% YoY | +21.4% QoQ) ■ EBITDA Margin (%): 10.3 (+808 bps YoY | +116 bps QoQ) ■ PAT: -61.0 (+82.5% YoY | +17.6% QoQ) ■ EPS (INR): -0.49 (+82.7% YoY | +18.3% QoQ) Hikal Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance Pharmaceuticals ■ Revenue: 2,778 (+46.6% YoY | +19.1% QoQ) ■ EBIT: 128 (Loss to Profit YoY | +70.7% QoQ) ■ EBIT Margin (%): 4.6 (Loss to Profit YoY | +139 bps QoQ) Crop protection and speciality ingredients ■ Revenue: 1,564 (+21.2% YoY | -7.7% QoQ) ■ EBIT: -23.0 (+76.0% YoY | +61.7% QoQ) ■ EBIT Margin (%): -1.5 (+597 bps YoY | +207 bps QoQ)
Press Release on Hikal signs Multi-Year Global CDMO contract with leading Agrochemical Company
Press Release · 02 Nov 2026, 1:36 pm
Hikal Secures Multi-Year Global Agrochemical CDMO Contract Hikal Limited’s Crop Protection division has signed a multi-year global CDMO contract with a Europe-based agrochemical major to supply a specialized agrochemical product worldwide. The agreement follows nearly three years of collaborative process development and scale-up by Hikal. Commercial launch is slated towards the end of FY27, with supply volumes expected to expand progressively as global regulatory approvals are obtained, strengthening Hikal's long-term crop protection manufacturing pipeline.
Press Release on Hikal''s Bengaluru API facility earns Swissmedic GMP Certification
Press Release · 30 Oct 2026, 1:37 pm
Hikal Secures Swissmedic GMP Certification for Bengaluru API Facility Hikal announced on 30th Oct'26 that Swissmedic has granted a Certificate of GMP Compliance to its Bengaluru API facility, confirming compliance with EU-Switzerland Mutual Recognition Agreement standards. This approval follows prior successful inspections by Brazil’s ANVISA and Japan’s PMDA. The regulatory milestone strengthens the facility's compliance standing, expands commercial access to European and key regulated markets, and supports the company’s strategic objective to geographically diversify its pharmaceutical business.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 03 Nov 2026, 5:30 am
Hikal Limited has informed the Exchange about Board Meeting to be held on 03-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 03 Nov 2026, 5:30 am
Intimation for Earning Group Conference Call
Intimation · 03 Nov 2026, 5:00 pm
Hikal Schedules Q2 & H1FY27 Earnings Conference Call for 3rd Nov'26 Hikal Limited will host its Q2 & H1FY27 earnings conference call on Tuesday, 3rd Nov'26, at 5:00 PM IST to discuss financial and operational performance for the period ended 30th Sep'26. Senior leadership participating includes CMD Sameer Hiremath, CFO Kuldeep Jain, CEO of Animal Health & Speciality Ingredients Anish Swadi, President of Pharmaceuticals Manoj Mehrotra, and Business Head of Crop Protection Ravi Khadabadi. Universal dial-in access numbers are +91 22 6280 1309 and +91 22 7115 8210.
Hikal Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Standalone and Consolidated Unaudited ....
Intimation · 03 Nov 2026, 5:30 am
Hikal Schedules Board Meeting to Approve Q2 and H1 Financial Results Hikal Limited announced that its Board of Directors will meet on 3rd Nov'26 to consider, approve, and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26.
Resignation of Mrs. Sugandha Hiremath as Non-Executive Director of the Company.
Change in Management · 01 Oct 2026, 7:11 pm
Hikal Announces Key Board Leadership Transitions and Senior Management Appointment Hikal Ltd announced that founder Mr. Jai Hiremath ceased his term as Executive Chairman, effective 1st Oct'26, and was conferred the honorary position of Chairman Emeritus for five years. Mrs. Sugandha Hiremath resigned as Non-Executive Director effective close of business on 30th Sep'26 due to personal commitments. Additionally, the Board approved the appointment of Mr. Anish Swadi as CEO – Animal Health and Specialty Ingredients, effective 1st Oct'26, elevating him within the senior management team.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015- Change in Management
Change in Management · 01 Oct 2026, 7:08 pm
Hikal Announces Key Board Leadership Transitions and Senior Management Appointment Hikal Ltd announced that Executive Chairman Jai Hiremath ceased his term effective 1st Oct'26, transitioning to an honorary "Chairman Emeritus" role for five years without board or KMP capacity. Additionally, Non-Executive Director Sugandha Hiremath resigned effective close of business 30th Sep'26 citing personal commitments. Concurrently, the board approved the appointment of Anish Swadi as CEO – Animal Health and Specialty Ingredients, effective 1st Oct'26, promoting him from his previous role as Senior President of Business Transformation and Animal Health.
Outcome of Board Meeting held today i.e. October 01, 2026
Others (Uncategorized) · 01 Oct 2026, 7:01 pm
Hikal Announces Key Board Leadership Transitions and Senior Management Appointment Hikal Ltd announced the cessation of founder Jai Hiremath's term as Executive Chairman effective 1st Oct'26; he has been conferred the honorary title of Chairman Emeritus for five years without board or managerial authority. Non-Executive Director Sugandha Hiremath resigned effective close of business 30th Sep'26 due to personal commitments, stepping down from all board committees. Additionally, the Board approved the appointment of Anish Swadi as CEO-Animal Health and Specialty Ingredients, a senior management position, effective 1st Oct'26.
Intimation of Disclosure under Regulation 30 of The Securities Exchange Board of India ( Listing Obligations and Disclosure Requirements) Regulations, 2015 - ESG Rating
Others (Uncategorized) · 29 Sept 2026, 9:45 pm
Crisil ESG Ratings Assigns 'Crisil ESG 65' to Hikal for FY26 Crisil ESG Ratings & Analytics assigned an unsolicited ESG rating of 'Crisil ESG 65' to Hikal Limited for FY26 under the Pharmaceuticals sector, per its report dated 28th Sep'26. Hikal outperformed peers across renewable energy mix, waste recycling, low water withdrawal in stressed zones, employee safety, zero recalls, and low complaint intensity. Governance metrics reflected strong board diversity, high independent director attendance, and zero whistleblower or investor complaints. The independent rating was derived entirely from public domain data without direct company engagement.
Press Release- Hikal ventures into Personal Care: New cGMP Panoli facility begins Commercial Production.
Press Release · 22 Sept 2026, 7:08 pm
Hikal Commences Commercial Production for Personal Care at Panoli Facility Hikal Limited announced on 22nd Sep'26 the start of commercial production for its Personal Care segment following the commissioning of a repurposed, cGMP-compliant multipurpose facility at Panoli, Gujarat. The initial operational focus targets the skincare market with second-generation UV filters undergoing global customer approvals, diversifying revenue beyond core Pharma and Crop Protection. Additionally, the company recently commissioned a cGMP pilot plant at Pune to scale CDMO capabilities and achieved an EcoVadis Gold Medal rating, positioning it in the top 5% of assessed companies globally.
Intimation of Analyst and Investor meet pursuant to regulations 30 of SEBI (LODR) Regulations, 2015
Intimation · 02 Sept 2026, 3:54 pm
Pursuant to Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015-Letter to members providing weblink to access the Annual Report for FY 2025-26
Annual Report · 31 Aug 2026, 10:29 pm
Business Responsibility and Sustainability Report for the Financial Year 2025-26
Others (Uncategorized) · 31 Aug 2026, 9:54 pm
Hikal FY26 BRSR Highlights ESG Progress and Key Financial Metrics Hikal's FY26 BRSR reports exports contributing 69% of turnover, which stood at ₹17,126 million. Revenue is split between Pharmaceutical Products (60%) and Basic Chemicals (40%). The company employs 2,077 people and had a permanent employee turnover rate of 31%. For FY26, total energy consumption was 1,345,295 GJ with 78% from renewable sources. Scope 1 and 2 GHG emissions were 53,710 MTCO₂e. Accounts payable days increased to 133 from 123 in FY25. The company reported zero work-related fatalities.
Annual Report for the financial year 2025-26
Others (Uncategorized) · 31 Aug 2026, 9:50 pm
Notice of the 38th Annual General Meeting of the Company
Annual General Meeting · 31 Aug 2026, 8:57 pm
Kindly find communication shared with shareholders.
Dividend · 27 Aug 2026, 10:24 pm
Hikal Announces Final Dividend and Sets Record Date for FY26 Hikal's board recommended a final dividend of Rs. 0.40 per share (face value Rs. 2) for FY26, pending shareholder approval at the AGM on 23 Sep'26. The record date for determining shareholder eligibility is set for 04 Sep'26. The company has communicated procedures for Tax Deduction at Source (TDS), with a standard rate of 10% for residents with a valid PAN, and 20% for non-compliant or non-resident shareholders. The deadline for submitting tax-related documents for lower/nil withholding is 10 Sep'26.
The Board of Directors of the Company at its meeting held today, inter alia, has decided to hold the AGM of the Company on September 23, 2026. Please find attached intimation in this regard.
Intimation · 26 Aug 2026, 7:02 pm